Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
01/2010
01/28/2010US20100022584 Modulation of Glutamine Synthetase Activity
01/28/2010US20100022583 PYRIDINYL MODULATORS OF gamma-SECRETASE
01/28/2010US20100022582 Tetrahydroisoquinoline Compound and Medicinal Use Thereof
01/28/2010US20100022581 Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
01/28/2010US20100022580 New 2,3,4,5-tetrahydro-1h-pyrido[4,3-b]indole compounds and methods of use thereof
01/28/2010US20100022579 Substituted tetrahydroquinolines
01/28/2010US20100022578 Macrocyclic inhibitors of hepatitis c virus
01/28/2010US20100022577 Dry syrup containing loratadine
01/28/2010US20100022576 Stable and bioavailable formulations and a novel form of desloratadine
01/28/2010US20100022575 Oxymatrine compositions and related methods for treating and preventing chronic infectious diseases
01/28/2010US20100022574 Methods to Treat Pain Using an Alpha-2 Adrenergic Agonist and an Endothelin Antagonist
01/28/2010US20100022573 Inhibitors of akt activity
01/28/2010US20100022572 Novel spiro compound and medicine comprising the same
01/28/2010US20100022571 Substituted pyrazolo [3,4-b]pyridines as phosphodiesterase inhibitors
01/28/2010US20100022569 Inhibitors of tyrosine kinases
01/28/2010US20100022568 Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
01/28/2010US20100022567 Compositions containing pufa and/or uridine and methods of use thereof
01/28/2010US20100022566 Quinazoline derivatives and pharmaceutical compositions thereof
01/28/2010US20100022565 Pharmaceutical compositions
01/28/2010US20100022564 Purine and deazapurine derivatives as pharmaceutical compounds
01/28/2010US20100022563 Phosphodiesterase inhibitor treatment
01/28/2010US20100022562 Use of Plant Growth Regulators to Reduce Abscisic Acid Related Plant Leaf Yellowing
01/28/2010US20100022561 Inhibitors of bruton's tyrosine kinase
01/28/2010US20100022560 Thiophene pyrazolopyrimidine compounds
01/28/2010US20100022558 Treatment of insomnia
01/28/2010US20100022557 Radioprotector compounds and related methods
01/28/2010US20100022556 Therapeutic combinations comprising a long acting dihydropyridine calcium-channel blocker and a statin
01/28/2010US20100022555 Novel Derivatives
01/28/2010US20100022554 Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia
01/28/2010US20100022553 Therapeutic Combination Comprising an Aurora Kinase Inhibitor and Imatinib
01/28/2010US20100022552 Kmup-1 capable of treating hypertension
01/28/2010US20100022551 Trimetazidine for use in the treatment of fibromyalgia syndrome and related conditions
01/28/2010US20100022550 Tetrahydrocarbazole derivatives useful as androgen receptor modulators
01/28/2010US20100022549 Alpha-helix mimetic with functionalized pyridazine
01/28/2010US20100022548 Use of n-heterocyclylmethylbenzamides in therapeutics
01/28/2010US20100022547 Compounds and Methods for Treating Mammalian Gastrointestinal Parasitic Infections
01/28/2010US20100022546 Adamantyl diamide derivatives and uses of same
01/28/2010US20100022545 Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators - 286
01/28/2010US20100022544 Cyclically substituted 3,5-dicyano-2-thiopyridines and use thereof
01/28/2010US20100022543 Cycloalkylidene and heterocycloalkylidene inhibitor compounds
01/28/2010US20100022542 Compounds exhibiting thrombopoietin receptor agonism
01/28/2010US20100022541 Chemical inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors
01/28/2010US20100022540 Triazole derivatives ii
01/28/2010US20100022539 Isoxazole Compounds as Histamine H3 modulators
01/28/2010US20100022538 5-fluoro pyrimidine derivatives
01/28/2010US20100022537 I-pheny 1-3,4-dihydropyrimidin-2(1h)-one derivatives and their use
01/28/2010US20100022536 Inhibitors of Cytosolic Phospholipase A2
01/28/2010US20100022535 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 Inhibitors
01/28/2010US20100022534 2-benzimidazolyl-6-morpholino-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
01/28/2010US20100022533 Compositions and methods for inducing cell dedifferentiation
01/28/2010US20100022532 1H-thieno[2,3-c]pyrazoles, showing a high affinity for the ATP pocket of ABL tyrosine kinase; compounds are thus ATP-competitive tyrosine kinase inhibitors displaying a significant inhibitory potency towards BCR-ABL inhibitor-resistant T315I ABL mutants; imatinib-resistant chronic myelogenous leukemia
01/28/2010US20100022531 Novel compounds as p2x7 modulators and uses thereof
01/28/2010US20100022530 Tetrahydrobenzoisoxazole and tetrahydroindazole derivatives as modulators of the mitotic motor protein
01/28/2010US20100022529 Amidophenoxyindazoles useful as inhibitors of c-met
01/28/2010US20100022528 Tetra-substituted ndga derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
01/28/2010US20100022527 Biphenyl substituted spirotetronic acids and their use for the treatment of retroviral diseases
01/28/2010US20100022525 Arginine Derivatives with NP-I Antagonistic Activity
01/28/2010US20100022524 Tricyclic tetrahydroquinoline antibacterial agents
01/28/2010US20100022523 3-aminobenzamide compounds and vanilloid receptor subtype 1 (vr1) inhibitors
01/28/2010US20100022522 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
01/28/2010US20100022521 Compounds
01/28/2010US20100022520 Malonyl-coa acetyltransferase inhibitors against antibiotic resistant bactertia
01/28/2010US20100022519 Heterocyclic-substituted piperidine compounds and the uses thereof
01/28/2010US20100022518 Novel heterocyclyl compounds
01/28/2010US20100022517 Ophthalmic formulation of rho kinase inhibitor compound
01/28/2010US20100022516 4,5-Disubstituted-2-aryl pyrimidines
01/28/2010US20100022515 Compounds and compositions as modulators of gpr119 activity
01/28/2010US20100022514 Heterocycle Compounds and Methods of Use Thereof
01/28/2010US20100022513 Organic compounds
01/28/2010US20100022512 Compositions of chk1 inhibitors and cyclodextrin
01/28/2010US20100022511 Stabilized Atypical Antipsychotic Formulation
01/28/2010US20100022510 Crystalline Forms
01/28/2010US20100022509 Inhibitors of MshC and Homologs Thereof, and Methods of Identifying Same
01/28/2010US20100022508 Antiviral compounds
01/28/2010US20100022507 Aminopyrimidines useful as inhibitors of protein kinases
01/28/2010US20100022506 Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
01/28/2010US20100022505 Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
01/28/2010US20100022504 Methods for treating latent tuberculosis
01/28/2010US20100022503 tyrosine kinase inhibitors such as Ethyl 3-(3-(pyrrolo[1,2-f][1,2,4]triazin-4-ylamino)-1H-pyrazol-5-ylthio)benzoate, useful as anticarcinogenic or antiproliferative agents
01/28/2010US20100022502 Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
01/28/2010US20100022501 such as drinabant (N-{1-[bis(4-chlorophenyl)methyl]-azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide) with an excipient selected from Polysorbate 80 or PEG hydroxystearate; drinkable dosage forms
01/28/2010US20100022500 Macrocyclic Lactams and Pharmaceutical Use Thereof
01/28/2010US20100022499 Heterocyclic compounds, combinatorial libraries thereof and methods of selecting drug leads
01/28/2010US20100022498 Steroids as agonists for fxr
01/28/2010US20100022497 Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject
01/28/2010US20100022496 Galenical form for the administration of active ingredients by transmucous means
01/28/2010US20100022495 Modulating endoplasmic reticulum stress in the treatment of tuberous sclerosis
01/28/2010US20100022494 Method, device, and kit for maintaining physiological levels of steroid hormone in a subject
01/28/2010US20100022493 Use of mometasone furoate for treating airway passage and lung disease
01/28/2010US20100022492 Therapeutic causing contraction of mucosal tissue, method of treating diseases relating to mucosal tissues, injector and therapeutic set
01/28/2010US20100022491 4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7yl compounds for modulation of b2-adrenoreceptor activity
01/28/2010US20100022490 Zilpaterol Enantiomer Compositions and Methods of Making and Using Such Compositions
01/28/2010US20100022489 Method, device, and kit for maintaining physiological levels of steroid hormone in a subject
01/28/2010US20100022488 Method, device, and kit for maintaining physiological levels of steroid hormone in a subject
01/28/2010US20100022487 Method, device, and kit for maintaining physiological levels of steroid hormone in a subject
01/28/2010US20100022486 Compounds
01/28/2010US20100022485 Formulations comprising a vitamin and the use thereof to make fortified feed and personal care formulations
01/28/2010US20100022484 4-Chromenonyl-1,4-dihydropyridines and their use
01/28/2010US20100022483 Substituted Tetracycline Compounds
01/28/2010US20100022482 aSMase inhibitors